Miltefosine in cutaneous leishmaniasis

Journal of the College of Physicians and Surgeons Pakistan

Volumn 17, Issue 3, 2007, Pages 132-135

  Rahman, Simeen Ber ^a   Ul Bari, Arfan ^b   Mumtaz, Nadeem ^a  

^a MILITARY HOSPITAL   (Pakistan)

^b Combined Military Hospital ^*  (Pakistan)

Author keywords

Antimonials; Cutaneous leishmaniasis; Miltetosine

Indexed keywords

ANTIMONY; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; MEGLUMINE; MEGLUMINE ANTIMONIATE; MILTEFOSINE; ORGANOMETALLIC COMPOUND; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; SKIN LEISHMANIASIS;

ADULT; ANTIMONY; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLCHOLINE;

EID: 34548393645     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Grevetink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996; 34: 257-272
2. Khan SJ, Muneeb S. Cutaneous leishmaniasis in Pakistan. Dermatol Online J 2005; 11: 4.
3. Magill AJ. Leishmaniasis. In: Strickland GT, (edi). Hunter's tropical medecine and emerging infectious diseases. 8th ed. Philadelphia: WB Saunders 2000: 665-687
4. Simeen ber Rehman, Arfan-ul-Bari. Laboratory profile in patients of cutaneous leishmaniasis from various regions of Pakistan, J coll Physicins Surg pak 2003; 13: 313-316
5. Mujtaba G, Khalid M. Cutaneous leishmaniasis in Multan, Pakistan, Int J Dermatol 1998; 37: 843-846
6. Kolaczinski J, Brooker S, Reyburn H, Rowland M. Epidemiology of anthroponotic cutaneous leishmaniasis in Afghan refugee camps in North-West Pakistan. Trans R Soc Trop Med Hyg 2004; 98: 373-378
7. Simeen ber Rehman, Arfan-ul-Bari. Morphological patterns of cutaneous leishmaniasis seen in Pakistan. J Pak Assoc Dermatol 2002; 12: 122-129
8. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296-306.
9. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-126
10. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006; 123:359-410.
11. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61: 223-274
12. Berman JD. Development of miltefosine for the leishmaniases. Mini Rev Med Chem 2006; 6: 145-151
13. Soto J, Soto P. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 2006; 4: 177-185
14. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004: 38: 1266-1272
15. Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 2005; 40: e120-4.
16. Nakayama H, Loiseau PM, Bories C, Torres de Ortiz S, Schinini A, Serna E, et al. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 2005; 49: 4950-4956
17. Zerpa O, Blanco B, Kannee C, Ulrich M, Sindermann H, Engel J, et al. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int J Dermatol 2006; 45: 751-753
18. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection Clin Infect Dis 2006; 43: 357-364
19. Minodior P, Noel G, Blank P, Uters M, Retornaz K, Garnier GM. Management of cutaneous leishmaniases in adults and children. Med Trop 2005; 65: 487-495